top of page

A Note to Our Readers: Our health blog sometimes features articles from third-party contributors. We share ideas and inspiration to guide your wellness journey—but remember, it’s not medical advice. If you have any health concerns or ongoing conditions, always consult your physician first before starting any new treatment, supplement, or lifestyle change.

SS-31 Peptide for Skin Aging: What UV Research Shows—and What It Doesn’t

Writer: Monica Pineider
Monica Pineider
2 hours ago
9 min read

Research-focused overview


Could a peptide that targets mitochondrial membranes help explain how skin responds to ultraviolet (UV) exposure? Researchers are exploring that question with SS-31, also known as elamipretide or MTP-131. A 2025 laboratory study tested an experimental milk-derived exosome formulation carrying SS-31 in UV-exposed skin-cell models. The results are scientifically interesting, but they do not show that SS-31 prevents wrinkles or treats photoaged skin in people.


The phrase SS-31 peptide for skin aging describes an emerging research question, not an established skincare use. This article explains what the 2025 study found, what it cannot tell us, and how SS-31’s research use differs from an FDA-approved medicine and from topical cosmetic peptides.


Scientist in a lab coat looking through a microscope in a laboratory.
Laboratory work can help researchers test early hypotheses about mitochondrial peptides and skin-cell responses; this image is illustrative and does not depict the cited study.

Quick Answer

A 2025 preclinical study reported that milk-exosome-loaded SS-31 (Exo-SS31) reduced oxidative-stress markers and altered collagen-degradation-related signals in UV-exposed human dermal fibroblasts. This is not proof of benefit or safety in people using an SS-31 serum, cream, or research product. In the United States, a specific injectable elamipretide product, Forzinity, has accelerated FDA approval for improving muscle strength in eligible people with Barth syndrome—not for skin aging or cosmetic use.


Key Takeaways


  • SS-31 is a synthetic mitochondrial-targeting tetrapeptide studied for its interaction with cardiolipin and mitochondrial function. Unlike conventional cosmetic peptides that primarily target skin signaling pathways, SS-31 peptide acts on mitochondrial membranes, making it an emerging compound in cellular aging and dermatological research.

  • The 2025 skin paper examined Exo-SS31, an experimental formulation combining SS-31 with milk-derived exosomes; it is not the same as an ordinary skincare serum or a research-vendor vial.

  • Findings involving UV-exposed fibroblasts and preclinical models cannot establish that SS-31 prevents wrinkles, reverses photoaging, or is safe and effective as a topical treatment in humans.

  • Forzinity (elamipretide) received accelerated FDA approval in 2025 for a specific injectable use in adults and children with Barth syndrome who weigh at least 30 kg. That approval does not cover skin aging.

  • Kylo Peptides describes its SS-31 peptide as for laboratory research only and not for human or veterinary use.

  • Broad-spectrum sun protection remains a better-supported way to reduce UV-related skin damage. Ask a dermatologist about treatment options for existing photoaging or changing skin lesions.



Table of Contents




How Mitochondria Relate to Skin Photoaging


Mitochondria help cells produce energy and take part in processes that regulate cellular metabolism and stress responses. UV exposure can damage skin through several pathways, including DNA damage, reactive oxygen species (ROS), inflammation, and changes to collagen-regulating enzymes. Mitochondrial stress is one area of active photoaging research, not the only explanation for visible skin aging.


A review of mitochondrial dysfunction in UV-induced photoaging describes links among UV exposure, ROS, and mitochondrial function. These mechanisms help researchers select laboratory questions; they do not by themselves prove that a mitochondrial-targeting compound will improve a person’s skin.


Photoaging also varies with cumulative sun exposure, age, genetics, skin tone, smoking, and other factors. For practical guidance on skin care and cosmetic evidence, see A to Zen’s Skin Health Hub, which covers skin health, healthy aging, and treatment safety.



What SS-31 Is


SS-31 is a synthetic tetrapeptide, a short chain of four amino-acid residues. Its sequence is commonly written D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2′,6′-dimethyltyrosine. It is also called MTP-131 and elamipretide.


Laboratory and preclinical research has examined SS-31’s interaction with cardiolipin, a phospholipid found in the inner mitochondrial membrane. A mechanistic paper describes SS-31 binding to membrane lipids and effects on membrane surface properties; the exact biological pathways and how findings translate across tissues remain research questions.


Read the primary research on SS-31 and mitochondrial membrane interactions.

Interest in mitochondrial targeting is not evidence that SS-31 can be absorbed through skin, delivered to skin-cell mitochondria from a cosmetic formulation, or used safely outside an approved clinical setting. A to Zen’s broader explainer on cellular health and peptide research discusses why evidence and safety need to be evaluated peptide by peptide.



What the 2025 UV Study Found


A 2025 paper in the Journal of Photochemistry and Photobiology B: Biology described Exo-SS31, an experimental complex in which researchers loaded SS-31 into milk-derived exosomes. The PubMed abstract reports work involving UV-exposed human dermal fibroblasts and lists animal models in the indexed subject terms. It does not report a clinical trial showing that people had fewer wrinkles or improved skin elasticity.


The researchers reported that Exo-SS31:


  • reduced ROS production in UV-exposed fibroblast models;

  • affected levels of superoxide dismutase (SOD) and glutathione (GSH), which are involved in antioxidant defenses;

  • reduced expression of MMP-1 and MMP-3, enzymes associated with extracellular-matrix breakdown; and

  • influenced UV-related pMAPK and AP-1 signaling markers.


The authors also reported stronger effects for Exo-SS31 than SS-31 alone in the experimental setting. That comparison applies to the formulation and conditions they tested. It does not establish that exosomes improve topical delivery in people, that the same effect occurs with a retail product, or that changes in laboratory markers translate into visible or lasting clinical benefit.


Read the primary paper, “Milk-derived exosome-loaded SS31 as a novel strategy to mitigate UV-induced photodamage in skin”. One author affiliation listed in PubMed is TINGO Exosomes Technology Co.; the authors declared no known competing financial interests or personal relationships that they believed could have influenced the work. This disclosure is context for readers, not evidence that the findings are invalid.


Laboratory researcher examining a sample with a microscope and dropper.
The reported Exo-SS31 findings are preclinical and should not be read as proof of a human skincare benefit.


What the Study Cannot Establish


The study does not establish that SS-31:


  • prevents or reverses wrinkles in humans;

  • improves skin elasticity, pigmentation, or appearance when applied topically;

  • reaches skin-cell mitochondria through a consumer cream or serum;

  • has a safe or effective cosmetic dose, route, or schedule;

  • works in the same way without the experimental milk-derived exosome carrier; or

  • can replace sunscreen, dermatological care, or approved treatment.


The results are early-stage evidence that may justify further research. Human studies would need to evaluate the specific formulation, delivery method, safety, dose, and patient-relevant outcomes before a skin-aging benefit could be established.


The linked Kylo Peptides product page we linked is a commercial supplier listing that identifies its material as laboratory research use only and not for human or veterinary use. Do not apply, inject, ingest, or otherwise use research-use-only material on or in people.



How SS-31 Differs From Cosmetic Peptides


Cosmetic peptides are ingredients in formulated topical products. Different cosmetic peptides are studied or marketed for different purposes, such as supporting the appearance of firmness or fine lines. Their performance depends on the specific ingredient, formulation, concentration, stability, and evidence for the product as used.


SS-31 is different: it is a mitochondrial-targeting peptide investigated in laboratory and medical research. The 2025 skin study’s Exo-SS31 formulation is not an established cosmetic ingredient or an approved anti-aging treatment. Do not infer a cosmetic benefit from the fact that other peptides appear in serums.


A to Zen’s article on peptide skincare and collagen support discusses topical cosmetic peptides separately from experimental peptide drugs. Claims and evidence for one peptide cannot be transferred to another.



FDA-Approved Elamipretide and Skin Research Are

Different


As of this article’s update, the FDA has approved a specific injectable elamipretide product, Forzinity, under the accelerated-approval pathway to improve muscle strength in adults and pediatric patients with Barth syndrome who weigh at least 30 kg. The approved product is administered by subcutaneous injection, and continued approval may depend on confirmatory evidence. See the FDA announcement and prescribing information.


That narrow approval does not mean that every product sold as SS-31 or elamipretide is FDA-approved, and it does not authorize use for skin aging, UV protection, or cosmetic treatment. A drug approval is specific to the product, formulation, route, population, and indication in its label. It does not validate Exo-SS31 as a skincare product.


For more context on the difference between research compounds and medical treatment, read A to Zen’s guide to research compounds and cellular wellness. A to Zen Therapies does not provide SS-31 treatment, peptide therapy, or dermatological diagnosis.



What to Do for Everyday Photoaging Prevention


For everyday prevention, the American Academy of Dermatology recommends choosing sunscreen that is broad spectrum, water resistant, and SPF 30 or higher, along with seeking shade and using sun-protective clothing. Its sunscreen selection guidance explains what those label terms mean.


Some people may benefit from topical retinoids or retinol for selected concerns, but these can irritate skin and are not appropriate for everyone. The AAD’s retinoid and retinol guidance advises discussing use with a dermatologist, especially for sensitive skin or specific health circumstances. Do not start a prescription product or stop prescribed treatment based on this article.


A new or changing spot, a lesion that bleeds or does not heal, or a persistent skin concern should be assessed by an appropriately qualified clinician. Cosmetic treatment is not a substitute for evaluating a possible skin disease.


Woman applying sunscreen to her leg outdoors.
Sun protection remains a practical, evidence-supported step for reducing UV exposure and premature skin aging.


Evidence Snapshot

The direct skin evidence highlighted here is a 2025 preclinical study of an experimental milk-exosome/SS-31 complex. It reports cellular markers in UV-exposed fibroblast models; the indexed record includes animal-model subject terms. It does not establish safety or effectiveness for topical SS-31 in people. Separately, Forzinity’s accelerated FDA approval is for a specific injectable product and Barth syndrome indication, not skin aging.

Expert Tip

When you see a peptide described as “promising,” check three things before accepting a skincare claim: which exact formulation was tested, in what model or population, and what outcome was measured? A change in ROS or MMP expression in a laboratory model is not the same outcome as fewer wrinkles in a clinical study.

Myth vs Fact


Myth

Fact

“SS-31 has been shown to reverse skin aging.”

The 2025 evidence is preclinical; it does not demonstrate wrinkle reversal in people.

“The exosome study proves SS-31 serum works.”

The study tested an experimental milk-derived exosome-loaded formulation, not ordinary retail serums.

“FDA approval of elamipretide means SS-31 is approved for skin.”

Forzinity’s accelerated approval is for a specific injectable use in people with Barth syndrome who meet the label criteria.

“If a supplier sells SS-31, it is suitable for personal use.”

The linked commercial supplier labels its product for laboratory research and not human or veterinary use.

“A mitochondrial mechanism means fewer wrinkles.”

A proposed biological mechanism does not establish a visible clinical benefit.



Conclusion


SS-31 peptide for skin aging remains an experimental research topic. The 2025 Exo-SS31 study offers a possible direction for investigating mitochondrial pathways and UV-related cellular stress, but it does not establish a safe or effective skin treatment for people.


Elamipretide’s FDA-approved use is limited to a specific injectable product and Barth syndrome indication. For established photoaging prevention, use sun-protection measures and seek dermatological advice for treatment decisions.



Frequently Asked Questions


Does SS-31 reduce wrinkles?


There is no established clinical evidence that SS-31 reduces wrinkles in people. The 2025 study reported laboratory findings with an exosome-loaded formulation, not clinical wrinkle outcomes.


Is SS-31 FDA approved?


A specific injectable elamipretide product, Forzinity, received accelerated FDA approval for improving muscle strength in eligible patients with Barth syndrome. This approval is not for skin aging, topical use, or cosmetic products.


Is SS-31 the same as a cosmetic peptide serum?


No. SS-31 is a mitochondrial-targeting peptide studied in research and in a specific prescription medicine. Cosmetic peptide serums use other ingredients and formulations; evidence for one peptide cannot be applied to another.


Can I apply research-grade SS-31 to my skin?


No. The linked supplier labels its product for laboratory research only and not for human or veterinary use. Research materials should not be used as skincare or self-administered.


What is Exo-SS31?


Exo-SS31 is the experimental formulation described in the 2025 paper, made by loading SS-31 into milk-derived exosomes. It is not an established consumer skincare product.


What is better supported for preventing UV-related skin aging?


Broad-spectrum, water-resistant SPF 30 or higher, shade, and protective clothing are established sun-protection measures recommended by dermatology guidance. A dermatologist can advise on treatments for existing signs of photoaging.



References


  1. Luo D, et al. (2025). Milk-derived exosome-loaded SS31 as a novel strategy to mitigate UV-induced photodamage in skin. Journal of Photochemistry and Photobiology B: Biology, 265, 113125. doi:10.1016/j.jphotobiol.2025.113125.

  2. Szeto HH, et al. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

  3. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics. (2020).

  4. U.S. Food and Drug Administration. (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.

  5. U.S. Food and Drug Administration. (2025). Forzinity (elamipretide) prescribing information.

  6. American Academy of Dermatology. How to select a sunscreen.

  7. American Academy of Dermatology. Retinoid or retinol?.

  8. Role of mitochondrial dysfunction in UV-induced photoaging and skin cancers. (2025 review).



Medical Disclaimer


This article is for general education and research literacy. It does not recommend SS-31 or elamipretide for skin aging, diagnose skin conditions, or replace medical advice. Do not use laboratory research products on or in people. Discuss prescription medicines, skin changes, and cosmetic treatments with a qualified clinician or dermatologist. Regulatory status and evidence may vary by country and can change.

Recent Posts

About the Author​

 

Monica Pineider is the author of the A to Zen Therapies health blog and founder of a Central London wellness clinic. She specialises in massage therapy and holistic treatments, drawing on professional experience since 2009 in reflexology, shiatsu, and deep tissue massage.

 

She trained in Thailand and Bali in traditional massage techniques before continuing advanced hands-on study in London across multiple therapy disciplines. This international and clinical background has shaped the approach and philosophy of A to Zen Therapies.

 

Monica oversees the editorial direction of every article published on the blog, including content written or contributed to by external specialists in areas beyond the clinic’s direct clinical experience. All content is reviewed to ensure clarity, accuracy, and alignment with our editorial standards.

 

She shares practical, experience-based insights to support relaxation, recovery, and everyday wellbeing.

​

​

⚠️ Medical Disclaimer

 

The information provided on this website is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment.

 

Always seek the advice of your physician, qualified healthcare provider, or other licensed medical professional regarding any medical condition, symptoms, or treatment options. Do not disregard professional medical advice or delay seeking it because of information you have read on this website.

 

A to Zen Therapies and its contributors provide information for general informational purposes only and may not reflect individual medical circumstances. Individual results from wellness practices, supplements, or natural therapies may vary.

 

If you are pregnant, nursing, taking medication, or have a pre-existing health condition, consult a qualified healthcare professional before starting any new wellness routine, supplement, or therapy.

 

Use of this website and its content is at your own risk.

​

​

Editorial Note

​

This article has been reviewed in accordance with A to Zen Therapies’ Editorial Policy to ensure accuracy, clarity, and responsible, experience-based wellness information.

bottom of page